The entity has beta of -0.0024 which indicates as returns on market increase, returns on owning SBI Pharma are expected to decrease at a much smaller rate. During bear market, SBI Pharma is likely to outperform the market. Although it is extremely important to respect SBI Pharma Reg current price movements, it is better to be realistic regarding the information on equity historical returns. The way of measuring future performance of any fund is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. By analyzing SBI Pharma Reg technical indicators you can today evaluate if the expected return of 0.0% will be sustainable into the future.
|Horizon||30 Days Login to change|
SBI Pharma Reg Relative Risk vs. Return LandscapeIf you would invest 11,803 in SBI Pharma Reg Gr on December 21, 2018 and sell it today you would earn a total of 0.00 from holding SBI Pharma Reg Gr or generate 0.0% return on investment over 30 days. SBI Pharma Reg Gr is generating negative expected returns and assumes 0.0% volatility on return distribution over the 30 days horizon. Simply put, 0% of equities are less volatile than SBI Pharma and 99% of equity instruments are likely to generate higher returns than the company over the next 30 trading days.
Daily Expected Return (%)
SBI Pharma Current Valuation
SBI Pharma is Unknown risk asset. SBI Pharma Reg current Real Value cannot be determined due to lack of data. The regular price of SBI Pharma Reg is 118.03. Based on Macroaxis valuation methodology, the entity cannot be evaluated at this time. We determine the value of SBI Pharma Reg from analyzing fund fundamentals and technical indicators as well as its Probability Of Bankruptcy. In general, we recommend to buy undervalued stocks and to dispose of overvalued stocks since in the future securities prices and their ongoing real values will draw towards each other.
SBI Pharma Market Risk Analysis
Sharpe Ratio = 0.0
Risk-Adjusted Fund PerformanceOver the last 30 days SBI Pharma Reg Gr has generated negative risk-adjusted returns adding no value to fund investors.
|Fifty Two Week Low||120.0020|
|Fifty Two Week High||128.0990|
|Annual Report Expense Ratio||2.73%|